Davis Polk advised the joint book-running managers and representatives of the several underwriters in the offering.Nurix Therapeutics, Inc. completed its follow-on offering of 5,175,000 shares of…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
